Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoxaline1 SCHEMBL1394500 | 1.00 | MAPT (0.52) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL5251534 | 0.76 | CYP1A2 (0.46) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL5247702 | 0.73 | ALDH1A1 (0.46) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL10333619 | 0.73 | GAA (0.57) | MAPTKMT2AMEN1CYP3A4CDK1 | |
| SCHEMBL29515180 | 0.69 | MAPT (0.62) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL13856236 | 0.68 | KMT2A (0.63) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL29444102 | 0.67 | MAPT (1.00) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL503252 | 0.67 | MAPT (1.00) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL29402115 | 0.67 | MAPT (0.71) | MAPTKMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL2246928 | 0.67 | MAPT (0.71) | MAPTKMT2AMEN1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108431209-B | Derived and mature hepatocyte types of liver stem cells and uses thereof | 新加坡科技研究局 | 2023-02-10 | — | — | CN | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-114207111-B | Method for producing skin-derived multipotent precursor cells | 花王株式会社 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4308153-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NUCLEOTIDE REPEAT EXPANSION | The General Hospital Corporation (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-108431209-B | Derived and mature hepatocyte types of liver stem cells and uses thereof | 新加坡科技研究局 | 2023-02-10 | — | — | CN | disclosed |
| WO-2022197857-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NUCLEOTIDE REPEAT EXPANSION | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114207111-A | Method for preparing skin-derived pluripotent precursor cells | 花王株式会社 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | MAPT 1671/4885KMT2A 674/4885MEN1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.